NATTO: NATTOPHARMA ASA EXERCISE OPTIONS
Oslo, Norway (10 November 2020) - The following options have been exercised:
| Name | Position | Number of options exercised | Exercise price | Shareholding after exercise | Options after exercise |
| Kjetil Ramsoy* | CEO | 50,000 | Kr 9.00 | 350,000 | 225,100 |
| Robert Schrama* | CFO | 30,000 | Kr 7.00 | 30,000 | 0 |
| Eric Anderson* | VP Business Development | 25,000 | Kr 9.00 | 75,000 | 116,750 |
| Rudi de Man* | VP Sales Europe & Asia | 41,500 | Kr 9.05 | 116,500 | 56,000 |
| 25,000 | Kr 9.00 | ||||
| 20,000 | Kr 9,20 | ||||
| Sjur Thorsheim* | Board Member | 50,000 | Kr 10.60 | 2,801,310 | 0 |
| 50,000 | Kr 14.00 | ||||
| Gunilla Traberg | Employee | 2,000 | Kr 9.00 | N/A | N/A |
| Anne Roksvåg | Employee | 10,000 | Kr 9.00 | N/A | N/A |
* Primary insider
Based on the power of attorney granted at the annual general meeting of NattoPharma ASA on June 19, 2020, the Board of Directors of NattoPharma has in board proceedings November 10, 2020 approved a share issue of 303,500 new shares, each with a face value of NOK 3 per share.
As a result, the share capital will be increased by NOK 910,500. After completing the share issue the Company’s new share capital will be NOK 59,530,299 divided into 19,843,433 shares, each with a face value of NOK 3.
For more information, please contact:
Robert Schrama, CFO, NattoPharma, robert.schrama@nattopharma.com
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.